High-flow nasal cannula in bronchiolitis: Modeling the economic effects of a ward-based protocol

OBJECTIVES: High-flow nasal cannula (HFNC) use has increased in patients with bronchiolitis, with the majority of use restricted to the ICU. Broadening HFNC to the wards may have substantial economic implications. This study compares the cost of a standardized clinical pathway that permits HFNC use in the wards for patients with bronchiolitis with an ICU-only HFNC care model. METHODS: We constructed a decision analytic model to simulate 2 options for treating bronchiolitic patients: One in which HFNC is used in the wards (ward HFNC) and one in which HFNC is restricted to the ICU (ICU HFNC). The model inputs were based on patients admitted with bronchiolitis without major comorbidities between 2010 and 2015. 1432 patients were included for analysis. We simulated 10 000 patients for 5000 trials to assess parameter variability and sampling uncertainty, respectively. The primary outcome was average admission cost per patient. The secondary outcome was average length of stay (LOS) per patient. RESULTS: In the model, the average admission cost per patient for the ward HFNC group was $7020 (95% confidence interval [CI] $6840-$7194) compared with $7626 (95% CI $7427-$7839) in the ICU HFNC group, with a net difference of $606 (95% CI $408-$795). The average LOS for the ward HFNC group was 2.29 days (95% CI 2.24-2.33) compared with 2.61 days (95% CI 2.56-2.66) in the ICU HFNC group, with a net difference of 0.32 days (95% CI 0.27-0.37). CONCLUSIONS: Using HFNC in the ward for bronchiolitis may be cost-effective and may decrease LOS compared with ICU-only HFNC.